Seeking AlphaCodex · 实盘不做把握 2/10
北京时间·🕒 发布 04:27:46时区推断·⟳ 抓取 04:27:53·⚡ 决策 08-04 11:07:59 +6h40m·84.2 天前
Amgen二季度财报前瞻关注新药增长、MariTide和约570亿美元债务
本条是财报发布前预览，市场已知共识为调整后EPS 5.62美元、收入94.2亿美元，尚无实际业绩 surprise。
📄 原文Seeking Alpha↗ 原文
Amgen Q2 preview: growth from newer drugs to offset legacy portfolio declines
Amgen (AMGN) will report second-quarter results on Tuesday, where the expectation is that strong growth from its newer…
不做 Amgen（AMGN.US）
财报前瞻不是实际业绩或指引变动，需等公司正式披露后由新信号判断。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 medium · price-in 风险 high ↗
关键理由
- 本条是财报发布前预览，市场已知共识为调整后EPS 5.62美元、收入94.2亿美元，尚无实际业绩 surprise。
主要风险
- 约570亿美元债务、老药竞争和定价压力属于预览中列出的存量关注点，不是当前确认的新净损害。
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,118 字
Amgen (AMGN) will report second-quarter results on Tuesday, where the expectation is that strong growth from its newer medicines continues to offset declines in older blockbuster products.
Analysts expect the drugmaker to report adjusted earnings of $5.62 per share, down 6.6% from a year earlier, on revenue of $9.42B, up 2.6%, according to consensus estimates.
The company heads into the quarter after posting first-quarter revenue and earnings that topped Wall Street expectations and raising its full-year outlook. Amgen now expects 2026 revenue of $37.1B to $38.5B and adjusted earnings of $21.70 to $23.10 per share, implying modest growth from last year.
Investors will be watching whether newer products, including cholesterol drug Repatha, osteoporosis treatment Evenity, and asthma medicine Tezspire, continue to post double-digit sales growth. Those medicines have become key growth drivers as sales of legacy products such as Enbrel and Prolia continue to decline following increased competition and pricing pressures.
Updates on Amgen's obesity candidate MariTide are also likely to remain a key focus. The company is evaluating the drug in multiple late-stage studies spanning obesity and related conditions, including cardiovascular disease and sleep apnea, with analysts viewing the program as one of Amgen's largest long-term growth opportunities.
Commentary on Amgen's broader late-stage pipeline, which spans about 30 Phase III programs across multiple therapeutic areas, will be closely watched.
While Amgen continues to generate strong cash flow, its balance sheet following recent acquisitions that lifted total debt to roughly $57B. Management has maintained that steady earnings growth, expanding contributions from newer medicines, and disciplined capital allocation should support long-term performance despite the leverage.
Over the last 2 years, AMGN has beaten EPS estimates 88% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 7 upward revisions and 18 downward. Revenue estimates have seen 6 upward revisions and 14 downward.
Analysts expect the drugmaker to report adjusted earnings of $5.62 per share, down 6.6% from a year earlier, on revenue of $9.42B, up 2.6%, according to consensus estimates.
The company heads into the quarter after posting first-quarter revenue and earnings that topped Wall Street expectations and raising its full-year outlook. Amgen now expects 2026 revenue of $37.1B to $38.5B and adjusted earnings of $21.70 to $23.10 per share, implying modest growth from last year.
Investors will be watching whether newer products, including cholesterol drug Repatha, osteoporosis treatment Evenity, and asthma medicine Tezspire, continue to post double-digit sales growth. Those medicines have become key growth drivers as sales of legacy products such as Enbrel and Prolia continue to decline following increased competition and pricing pressures.
Updates on Amgen's obesity candidate MariTide are also likely to remain a key focus. The company is evaluating the drug in multiple late-stage studies spanning obesity and related conditions, including cardiovascular disease and sleep apnea, with analysts viewing the program as one of Amgen's largest long-term growth opportunities.
Commentary on Amgen's broader late-stage pipeline, which spans about 30 Phase III programs across multiple therapeutic areas, will be closely watched.
While Amgen continues to generate strong cash flow, its balance sheet following recent acquisitions that lifted total debt to roughly $57B. Management has maintained that steady earnings growth, expanding contributions from newer medicines, and disciplined capital allocation should support long-term performance despite the leverage.
Over the last 2 years, AMGN has beaten EPS estimates 88% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 7 upward revisions and 18 downward. Revenue estimates have seen 6 upward revisions and 14 downward.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。